AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Avita Medical Q2 2025 Revenue at $18.4M, Projects $76M-$81M 2025 Revenue with Backlog Easing
ByAinvest
Friday, Aug 8, 2025 3:24 pm ET1min read
Avita Medical projects $76M-$81M revenue for 2025, with a rebound expected as the claims backlog eases. In Q2 2025, commercial revenue increased 21% YoY to $18.4M, but was flat sequentially due to a temporary headwind.
Avita Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, reported its second-quarter 2025 financial results, revealing a mixed performance marked by both growth and challenges. The company projects full-year 2025 revenue to range between $76 million and $81 million, down from previous guidance of $100 million to $106 million [1].In the second quarter, commercial revenue increased 21% year-over-year (YoY) to $18.4 million, but was flat sequentially due to a temporary headwind related to a reimbursement issue. The company experienced a significant reduction in demand for its flagship RECELL® System due to delays in Medicare Administrative Contractor (MAC) payments to providers. This issue, which began in January 2025, led to a backlog of unpaid claims, creating uncertainty among providers and dampening demand for the RECELL System [1].
Despite the headwind, Avita Medical's gross profit margin remained strong at 81.2% for the quarter, driven by deeper penetration within customer accounts and new accounts for trauma wounds. The company's gross margin for RECELL products was 84.3% for the quarter, indicating continued profitability for its core product line [1].
Total operating expenses decreased to $26.1 million in Q2 2025 from $28.7 million in Q2 2024, primarily due to reductions in sales and marketing expenses and general and administrative expenses. The company expects to continue reducing operating expenses by approximately $2.5 million per quarter going forward [1].
Avita Medical has taken steps to address the reimbursement issue, with multiple MACs indicating their intent to adjudicate and pay claims under the new codes in July. The company anticipates a recovery in RECELL demand in the second half of 2025 as the claims backlog is resolved [1].
The company's financial results were presented on a webcast and conference call on August 7, 2025, where executives discussed the second-quarter 2025 financial results and provided an outlook for the remainder of the year.
References:
[1] https://www.nasdaq.com/press-release/avita-medical-reports-second-quarter-2025-financial-results-updates-full-year
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet